Last updated: 2026-09-16 10:31:40. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Virax Biolabs Group Limited (VRAX) operates in the -- sector and is listed on NASDAQ. The stock is currently priced at $2.55, with a market capitalisation of $2.08M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $2.50 to $21.75. This page covers its latest market performance, valuation, price trends and company information.
$2.08M | |
$2.63 | |
$7,250.00 | |
$2.50 | |
$2.59 | |
919.00 | |
1.79M | |
-- | |
$21.75 | |
$2.50 | |
-- | |
-- |
Virax Biolabs Group Limited (VRAX) is trading at $2.55 in pre-market trading as of 2026-09-16 10:01:00, down 1.54% ($0.04) from the previous close of $2.59
Pre-market trading shows how investors are pricing VRAX before the regular session opens. The current pre-market price is below the previous close, indicating cautious early trading sentiment.
Over the past seven days, Virax Biolabs Group Limited (VRAX) moved from $2.63 to $2.55, representing a decline of 2.86% ($0.08).
The stock traded between $2.54 and $2.92 during the period. The latest price is near the lower end of the 7-day range, indicating moderate downward.
The average daily volume was 37.24 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 0.3%
VRAX is currently trading at $2.55, placing it 0.3% of the way from its 52-week low of $2.50 to its 52-week high of $21.75. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Virax Biolabs Group Ltd is a biotechnology company focused on the detection of immune responses and the development of immune profiling and in vitro diagnostic technologies for viral and immune-mediated diseases, with a current strategic focus on post-acute infection syndromes (PAIS) and related areas of chronic immune dysfunction. The company's principal development activities are centered on T cell-based in vitro diagnostics and immune profiling. The company's flagship product candidate, ViraxImmune, is an in-development T cell-based assay and immune profiling platform intended to support the assessment of immune dysfunction, initially in PAIS indications.
| Employees | 26 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Virax Biolabs Group Limited (VRAX) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.